It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

Key updates in the health sector have emerged, with AstraZeneca facing disappointment in a breast cancer drug trial. The ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

European stock markets rallied on Monday afternoon to finish with moderate gains as dismal economic data increased hopes that ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...